Compare SEDG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | OLMA |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.4B |
| IPO Year | 2015 | 2020 |
| Metric | SEDG | OLMA |
|---|---|---|
| Price | $38.28 | $16.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 10 |
| Target Price | $30.58 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 3.7M | 1.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.26 | 15.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,184,444,000.00 | N/A |
| Revenue This Year | $19.38 | N/A |
| Revenue Next Year | $13.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.39 | N/A |
| 52 Week Low | $11.45 | $3.89 |
| 52 Week High | $53.75 | $36.26 |
| Indicator | SEDG | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 49.19 |
| Support Level | $30.73 | $13.11 |
| Resistance Level | $42.15 | $16.99 |
| Average True Range (ATR) | 3.87 | 0.78 |
| MACD | -1.43 | 0.52 |
| Stochastic Oscillator | 7.71 | 85.19 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.